Skip to main content
NCBI home page
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2017 Jan 19;18(1):69–76. doi: 10.3233/CBM-160675

Distinctive expression pattern of OCT4 variants in different types of breast cancer

Saamaaneh Soheili a, Malek Hossein Asadi a,*, Alireza Farsinejad b
PMCID: PMC13020613  PMID: 27814277

Abstract

BACKGROUND:

OCT4 is a key regulator of self-renewal and pluripotency in embryonic stem cells which can potentially encode three spliced variants designated OCT4A, OCT4B and OCT4B1. Based on cancer stem cell concept, it is suggested that the stemness factors misexpressed in cancer cells and potentially is involved in tumorigenesis.

OBJECTIVE:

Accordingly, in this study, we investigated the potential expression of OCT4 variants in breast cancer tissues.

METHODS:

A total of 94 tumoral and peritumoral breast specimens were evaluated with respect to the expression of OCT4 variants using quantitative RT-PCR and immunohistochemical (IHC) analysis.

RESULTS:

We detected the expression of OCT4 variants in breast tumor tissues with no or very low levels of expression in peritumoral samples of the same patients. While OCT4B was highly expressed in lobular type of breast cancer, OCT4A and OCTB1 variants are highly expressed in low grade (I and II) ductal tumors. Furthermore, the results of this study revealed a considerable association between the expression level of OCT4 variants and the expression of ER, PR, Her2 and P53 factors.

CONCLUSIONS:

All data demonstrated a distinctive expression pattern of OCT4 spliced variants in different types of breast cancer and provide further evidence for the involvement of embryonic genes in carcinogenesis.

Keywords: OCT4 spliced variants, cancer stem cells, breast cancer

References

  • [1]. Nichols J., Zevnik B., Anastassiadis K., Niwa H., Klewe-Nebenius D., Chambers I., Schöer H. and Smith A., Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4, Cell 95 (1998), 379-391. [DOI] [PubMed] [Google Scholar]
  • [2]. Boiani M. and Schöer H.R., Regulatory networks in embryo-derived pluripotent stem cells, Nature Reviews Molecular Cell Biology 6 (2005), 872-881. [DOI] [PubMed] [Google Scholar]
  • [3]. Pardal R., Clarke M.F. and Morrison S.J., Applying the principles of stem-cell biology to cancer, Nature Reviews Cancer 3 (2003), 895-902. [DOI] [PubMed] [Google Scholar]
  • [4]. Al-Hajj M. and Clarke M.F., Self-renewal and solid tumor stem cells, Oncogene 23 (2004), 7274-7282. [DOI] [PubMed] [Google Scholar]
  • [5]. Clarke M.F. and Fuller M., Stem cells and cancer: two faces of eve, Cell 124 (2006), 1111-1115. [DOI] [PubMed] [Google Scholar]
  • [6]. Cao L., Li C., Shen S., Yan Y., Ji W., Wang J., Qian H., Jiang X., Li Z. and Wu M., OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma, BMC Cancer 13 (2013), 82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7]. Wen J., Park J.Y., Park K.H., Chung H.W., Bang S., Park S.W. and Song S.Y., Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis, Pancreas 39 (2010), 622-626. [DOI] [PubMed] [Google Scholar]
  • [8]. Wei D., Kanai M., Jia Z., Le X. and Xie K., Krüpel-like factor 4 induces p27Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells, Cancer Research 68 (2008), 4631-4639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9]. Papamichos S.I., Kotoula V., Tarlatzis B.C., Agorastos T., Papazisis K. and Lambropoulos A.F., OCT4B1 isoform: the novel OCT4 alternative spliced variant as a putative marker of stemness, Molecular Human Reproduction 15 (2009), 269-270. [DOI] [PubMed] [Google Scholar]
  • [10]. Atlasi Y., Mowla S.J., Ziaee S.A. and Bahrami A.R., OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer, International Journal of Cancer 120 (2007), 1598-602. [DOI] [PubMed] [Google Scholar]
  • [11]. Takeda J., Seino S. and Bell G.I., Human Oct3 gene family: cDNA sequences, alternative splicing, gene organization, chromosomal location, and expression at low levels in adult tissues, Nucleic Acids Research 20 (1992), 4613-4620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12]. Atlasi Y., Mowla S.J., Ziaee S.A.M., Gokhale P.J. and Andrews P.W., OCT4 Spliced Variants Are Differentially Expressed in Human Pluripotent and Nonpluripotent Cells, Stem Cells 26 (2008), 3068-3974. [DOI] [PubMed] [Google Scholar]
  • [13]. Lee J., Kim H.K., Rho J.Y., Han Y.M. and Kim J., The human OCT-4 isoforms differ in their ability to confer self-renewal, Journal of Biological Chemistry 281 (2006), 33554-33565. [DOI] [PubMed] [Google Scholar]
  • [14]. Cauffman G., Liebaers I., Van Steirteghem A. and Van de Velde H., POU5F1 isoforms show different expression patterns in human embryonic stem cells and preimplantation embryos, Stem Cells 24 (2006), 2685-2691. [DOI] [PubMed] [Google Scholar]
  • [15]. Asadi M.H., Mowla S.J., Fathi F., Aleyasin A., Asadzadeh J. and Atlasi Y., OCT4B1, a novel spliced variant of OCT4, is highly expressed in gastric cancer and acts as an antiapoptotic factor, International Journal of Cancer 128 (2011), 2645-2652. [DOI] [PubMed] [Google Scholar]
  • [16]. Asadzadeh J., Asadi M.H., Shakhssalim N., Rafiee M.R., Kalhor H.R., Tavallaei M. and Mowla S.J., A Plausible Anti-Apoptotic Role of Up-Regulated OCT4B1 in Bladder Tumors, Urology Journal 9 (2012), 574-580. [PubMed] [Google Scholar]
  • [17]. Mirzaei M.R., Najafi A., Arababadi M.K., Asadi M.H. and Mowla S.J., Altered expression of apoptotic genes in response to OCT4B1 suppression in human tumor cell lines, Tumor Biology 35 (2014), 9999-10009. [DOI] [PubMed] [Google Scholar]
  • [18]. Mirzaei M.R., Arababadi M.K., Asadi M.H. and Mowla S.J., Altered Expression of High Molecular Weight Heat Shock Proteins after OCT4B1 Suppression in Human Tumor Cell Lines, Cell Journal 17 (2016), 608-616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19]. Mirzaei M.R., Asadi M.H., Mowla S.J., Hassanshahi G. and Ahmadi Z., Down-regulation of HSP40 gene family following OCT4B1 suppression in human tumor cell lines, Iran J Basic Med Sci, 19 (2016), 187-193. [PMC free article] [PubMed] [Google Scholar]
  • [20]. Torre L.A., Bray F., Siegel R.L., Ferlay J., Tieulent J.L. and Jemal A., Global Cancer Statistics, 2012, CA: A Cancer Journal for Clinicians 65 (2015), 87-108. [DOI] [PubMed] [Google Scholar]
  • [21]. Schöer H.R., Ruppert S., Suzuki N., Chowdhury K. and Gruss P., New type of POU domain in germ line-specific protein Oct-4, Nature 29 (1990), 435-439. [DOI] [PubMed] [Google Scholar]
  • [22]. Rosner M.H., Vigano M.A., Ozato K., Timmons P.M., Poirie F., Rigby P.W. and Staudt L.M., A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo, Nature 345 (1990), 686-692. [DOI] [PubMed] [Google Scholar]
  • [23]. Radzisheuskaya A. and Silva J.C.R., Do all roads lead to Oct4? The emerging concepts of induced pluripotency, Trends in Cell Biology 24 (2014), 275-284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24]. Amin R. and Mishra L., Liver Stem Cells and TGF-β in Hepatic Carcinogenesis, Gastrointest Cancer Res 2 (2008), 27-30. [PMC free article] [PubMed] [Google Scholar]
  • [25]. Looijenga L.H., Stoop H., de Leeuw H.P.J.C., de Gouveia Brazao C.A., Gillis A.J.M., van Roozendaal K.E.P., van Zoelen E.J.J., Weber R.F.A., Wolffenbuttel K.P., van Dekken H., Honecker F., Bokemeyer C., Perlman E.J., Schneider D.T., Kononen J., Sauter G. and Oosterhuis J.W., POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors, Cancer Research 63 (2003), 2244-50. [PubMed] [Google Scholar]
  • [26]. Li X., Wang J., Xu Z., Ahmad A., Li E., Wang Y., Qin S. and Wang Q., Expression of Sox2 and Oct4 and their clinical significance in human non-small-cell lung cancer, International Journal of Molecular Sciences 13 (2012), 7663-75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27]. Ezeh U.I., Turek P.J., Reijo Pera R.A. and Clark A.T., Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma, Cancer 104 (2005), 2255-65. [DOI] [PubMed] [Google Scholar]
  • [28]. Gibbs C.P., Kukekov V.G., Reith J.D., Tchigrinova O., Suslov O.N., Scott E.W., Ghivizzani S.C., Ignatova T.N. and Steindler D.A., Stem-Like Cells in Bone Sarcomas: Implications for Tumorigenesis, Neoplasia 7 (2005), 967-976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29]. Jin T., Branch D.R., Zhang X., Qi S., Youngson B. and Goss P.E., Examination of POU homeobox gene expression in human breast cancer cells, International Journal of Cancer 81 (1999), 104-12. [DOI] [PubMed] [Google Scholar]
  • [30]. Wang Q., Zhang J.G. and Wang W., Expression and significance of S100P, CD147, and OCT4 in different prostate cancer tissue TNM stages, Genetics and Molecular Research 14 (2015), 6844-6851. [DOI] [PubMed] [Google Scholar]
  • [31]. Wang P., Branch D.R., Bali M., Schultz G.A., Goss P.E. and Jin T., The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells, Biochem J 375 (2003), 199-205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [32]. Tai M.H., Chang C.C., Olson L.K. and Trosko J.E., Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis, Carcinogenesis 26 (2005), 495-502. [DOI] [PubMed] [Google Scholar]
  • [33]. Wezel F., Pearson J., Kirkwood L.A. and Southgate J., Differential expression of Oct4 variants and pseudogenes in normal urothelium and urothelial cancer, The American journal of pathology 183 (2013), 1128-1136. [DOI] [PubMed] [Google Scholar]
  • [34]. Gazouli M., Roubelakis M.G., Theodoropoulos G.E., Papailiou J., Vaiopoulou A., Pappa K.I., Nikiteas N. and Anagnou N.P., OCT4 spliced variant OCT4B1 is expressed in human colorectal cancer, Molecular Carcinogenesis 51 (2012), 165-173. [DOI] [PubMed] [Google Scholar]
  • [35]. Hatefi N., Nouraee N., Parvin M., Ziaee S.A.M. and Mowla S.J., Evaluating the expression of oct4 as a prognostic tumor marker in bladder cancer, Iranian Journal of Basic Medical Sciences 15 (2012), 1154. [PMC free article] [PubMed] [Google Scholar]
  • [36]. Gao Y., Wei J., Han J., Wang X., Su G., Zhao Y., Chen B., Xiao Z., Cao J. and Dai J., The novel function of OCT4B isoform-265 in genotoxic stress, Stem Cells 30 (2012), 665-72. [DOI] [PubMed] [Google Scholar]
  • [37]. Li S.W., Wu X.L., Dong C.L., Xie X.Y., Wu J.F. and Zhang X., The Differential Expression of OCT4 Isoforms in Cervical Carcinoma, PLoS One 10 (2015), e0118033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [38]. Li D., Yang Z.K., Bu J.Y., Xu C.Y., Sun H., Tang J.B., Lin P., Cheng W., Huang N., Cui R.J., Yu X.G. and Zheng X.L., OCT4B modulates OCT4A expression as ceRNA in tumor cells, Oncology Reports 33 (2015) 2622-30. [DOI] [PubMed] [Google Scholar]
  • [39]. Jung J.W., Park S.B., Lee S.J., Seo M.S., Trosko J.E. and Kan K.S., Metformin Represses Self-Renewal of the Human Breast Carcinoma Stem Cells via Inhibition of Estrogen Receptor-Mediated OCT4 Expression, PLoS One 6 (2011), e28068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [40]. Beltran A.S., Rivenbark A.G., Richardson B.T., Yuan X., Quian H., Hunt J.P., Zimmerman E., Graves L.M. and Blancafort P., Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor, Breast Cancer Research 13 (2011), R94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41]. Simoes B.M., Piva M., Iriondo O., Comaills V., Loṕez-Ruiz J.A., Zabalza I., Mieza J.A., Acinas O. and Vivanco M.D.M., Effects of estrogen on the proportion of stem cells in the breast, Breast Cancer Res, Treat 129 (2011), 23-35. [DOI] [PubMed] [Google Scholar]
  • [42]. Stossi F., Likhite V.S., Katzenellenbogen J.A. and Katzenellenbogen B.S., Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter, Journal of Biological Chemistry 281 (2006), 16272-278. [DOI] [PubMed] [Google Scholar]
  • [43]. Oak P.S., Kopp F., Thakur C., Ellwart J.W., Rapp U.R., Ullrich A., Wagner E., Knyazev P. and Roidl A., Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells, International Journal of Cancer 131 (2012), 2808-2819. [DOI] [PubMed] [Google Scholar]
  • [44]. Karunagaran D., Tzahar E., Beerli R.R., Chen X., Graus-Porta D., Ratzkin B.J., Seger R., Hynes N.E. and Yarden Y., ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer, EMBO Journal 15 (1996), 254-264. [PMC free article] [PubMed] [Google Scholar]
  • [45]. Aranda V., Haire T., Nolan M.E., Calarco J.P., Rosenberg A.Z., Fawcett J.P., Pawson T. and Muthuswamy S.K., Par6 - aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control, Nature Cell Biology 8 (2006), 1235-1245. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES